Deciphera Pharmaceuticals Inc

NASDAQ:DCPH   2:18:04 PM EDT
8.38
-0.09 (-1.06%)
Layoffs, Products, Restructuring / Reorganization

Deciphera Pharmaceuticals Announces Restructuring To Prioritize Clinical Development Programs And Streamline Commercial Operations

Published: 11/30/2021 13:51 GMT
Deciphera Pharmaceuticals Inc (DCPH) - Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations.
Deciphera Pharmaceuticals Inc - Workforce Reduction of Approximately 35%.
Deciphera Pharmaceuticals Inc - Cash Runway Extended Into 2024.
Deciphera Pharmaceuticals Inc - US Commercial Operations Streamlined and Launches Planned in Select European Markets for Qinlock.
Deciphera Pharmaceuticals Inc - Resources Focused on Clinical Development of Vimseltinib and Dcc-3116; Rebastinib Program Discontinued.
Deciphera Pharmaceuticals - Will Remain Focused on Commercialization of Qinlock for Treatment of Fourth-line Gist in U.S. With Reduced Commercial Team.
Deciphera Pharmaceuticals - in Europe, Will Maintain Limited Direct Commercial Presence That Will Support Launch of Qinlock in Germany and France.
Deciphera Pharmaceuticals Inc - Further Clinical Development of Qinlock Will Be Discontinued, Including Phase 1b/2 Mek Combination Study.
Deciphera Pharmaceuticals - Expects to Initiate Phase 3 Motion Study for Vimseltinib for Treatment of Tenosynovial Giant Cell Tumor Before End of Year.
Deciphera Pharmaceuticals Inc - Deciphera Will Continue to Advance Clinical Development of Dcc-3116.
Deciphera Pharmaceuticals - Intends to Continue to Invest in Development of New Product Candidates Using Its Novel Switch-control Inhibitor Approach.